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Iron-overload disorders owing to genetic misregulation of iron acquisition are referred to
as hereditary hemochromatosis (HH). The most prevalent genetic iron overload disorder in
Caucasians is caused by mutations in the HFE gene, an atypical MHC class I molecule.
Recent studies classiﬁed HFE/Hfe-HH as a liver disease with the primarily failure in
the production of the liver iron hormone hepcidin in hepatocytes. Inadequate hepcidin
expression signals for excessive iron absorption from the diet and iron deposition in tissues
causing multiple organ damage and failure. This review focuses on the molecular actions
of the HFE/Hfe and hepcidin in maintaining systemic iron homeostasis and approaches
undertaken so far to combat iron overload in HFE/Hfe-HH. In the light of the recent
investigations, novel roles of extra-hepatocytic Hfe are discussed raising a question to
the relevance of the multipurpose functions of Hfe for the understanding of HH-associated
pathologies.
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AN ADEQUATE SUPPLY OF IRON IS A PREREQUISITE FOR
GOOD HEALTH
Iron overload disorders comprise a wide range of inherited and
acquired disorders of iron metabolism. Hereditary hemochro-
matosis (HH) encompasses a heterogenous group of inherited
iron overload disorders with distinct underlyingmolecular defects
and varying clinical symptoms (Camaschella and Poggiali, 2011).
HH begins as mere iron overload which over time can cause
serious organ dysfunctions leading to liver failure and cirrhosis,
hepatocellular carcinoma, atherosclerosis, arthritis, fatigue, var-
ious endocrinopathies including diabetes, heart problems (both
arrhythmia and cardiomyopathy, or loss of cardiac muscle func-
tion), hypermelanotic pigmentation of the skin, or compromised
immune defense (Davies and Enns, 2004; Camaschella, 2005;
Guggenbuhl et al., 2005; Pietrangelo,2010). If remaineduntreated,
HH is a life-threatening disorder. The current mainstay therapy
for HH is phlebotomy (venesections), a relatively simple and inex-
pensive treatment, whereby blood is removed on a weekly basis for
several months or more depending on the iron levels. For patients
undergoing phlebotomy, liver, and cardiac functions improve
after iron-depletion, whereas other HH-associated pathologies
(e.g., diabetes mellitus or arthropathy) are often unchanged by the
treatment (Brissot and de Bels, 2006; Sahinbegovic et al., 2010).
In certain cases, iron chelation therapy may be taken into
consideration (Brissot and de Bels, 2006). All current thera-
pies for HH focus exclusively at manipulating the excess of
iron.
LOW LEVELS OF HORMONE HEPCIDIN HALLMARK HH
Genetic data inmice andpatients demonstrated that a relative deﬁ-
ciency of hormonehepcidin underliesHHdisorders (Ahmad et al.,
2002; Bridle et al., 2003; Muckenthaler et al., 2003; Niederkoﬂer
et al., 2005;Wallace et al., 2005; Babitt et al., 2006; Lesbordes-Brion
et al., 2006;Wallace et al., 2009). Hepcidin is a liver-derived peptide
that oversees systemic iron changes by maintaining plasma iron
levels within a narrow physiological range. It does so by determin-
ing iron absorption and iron release from the cells through binding
to its receptor, the iron-export protein ferroportin (Nemeth et al.,
2004; Nemeth and Ganz, 2006). Low levels of hepcidin signal for
increased ferroportin activity thereby enhancing iron uptake from
the diet via enterocytes, iron release from macrophages into the
circulation and deposition of the excess of iron in parenchymal
cells of tissues leading to a condition of systemic iron overload.
The hepcidin-mediated ferroportin regulation can therefore be
considered as the critical step for balancing systemic iron lev-
els. Any disturbances in hepcidin regulators such as mutations
in HH-genes like HFE, Transferrin receptor 2 (TfR2; Roetto et al.,
2002; Kawabata et al., 2005; Nemeth et al., 2005), Hemojuvelin
(HJV ; Lanzara et al., 2004; Papanikolaou et al., 2004; Huang et al.,
2005; Niederkoﬂer et al., 2005; Babitt et al., 2006) orHepcidin itself
(Roetto et al., 2003; Lesbordes-Brion et al., 2006), and/or ferro-
portin (Pietrangelo, 2004; Sham et al., 2009; Le Lan et al., 2011)
contribute to iron-related pathophysiology (Ganz and Nemeth,
2006).
HFE-HH IS THE MOST COMMON TYPE OF HH IN WESTERN
POPULATION
The most common type of hereditary HH is associated with the
mutations in the HFE (High Fe) gene (Feder et al., 1996; Levy
et al., 1999; Bridle et al., 2003; Muckenthaler et al., 2003). This
is the most prevalent mutation in Western populations affect-
ing approx. 1:250 individuals (Pietrangelo, 2010). The HFE gene
was ﬁrst identiﬁed in 1996 as a major histocompatibility (MHC)
class I-like gene in which homozygosity for a missense muta-
tion that results in cystein-to-tyrosine substitution at amino acid
282 of human HFE protein (C282Y), was found in vast major-
ity of HH patients (Feder et al., 1996). Approximately 80% of
HH patients are homozygous for C282Y and the frequency of
this mutation decreases from the northwest to southwest Europe
paralleling the settlements of ancient Celts (Distante et al., 2004).
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It is likely that mutation provided survival advantage against
from what was then a very poor iron diet. Signiﬁcantly fewer
patients with a clinical diagnosis of HH are heterozygotes for a
compound C282Y and H63D mutation (the latter is a substitu-
tion of aspartic acid for histidine at the position 63 of the HFE
protein), whereas the homozygosity for H63D mutation usually
causes little increase in iron absorption and rarely leads to the
development of HH. Other mutations (e.g., S65C, V53M, V59M,
H63H, Q127H, Q283P, P168X, E168Q, E168X, W168X) are rare
and/or have low penetrance (Qaseem et al., 2005; Brissot et al.,
2011).
The discovery of the HFE gene and the identiﬁcation of the
mutations associated with the HFE-HH were spectacular. The
wealth of scientiﬁc and clinical data led towards more accurate
diagnosis of HFE-HH, improved family screening and provided
the ﬁrst insights into the regulation of iron homeostasis by the
HFE.
HFE-HH IS THE LIVER DISEASE
The protein encoded by the HFE gene is a non-classical MHC
class I-like protein which contains a signal sequence, peptide-
binding extracellular domains, a transmembrane region, and a
small cytoplasmic portion. Within the alpha-2 and alpha-3 extra-
cellular domains are the four cysteine residues that form disulﬁde
bridges representing one of the most conserved structural features
ofMHCclass Imolecules. HFE interactswith beta2-microglobulin
and this association enables efﬁcient transport of HFE to the
cell surface where it interacts with TfR1. C282Y mutation dis-
rupts the disulﬁde bridges in the extracellular domains of the
HFE protein thereby preventing the association of HFE with
beta2-microglobulin and TfR1. The lack of HFE interaction with
TfR1 increases the afﬁnity of TfR1 for the transferrin-bound
iron thereby modulating iron absorption. In contrast to the
C282Y mutation, mutant H63D HFE formed stable complexes
with TfR1 being in line with the clinical data that H63D HFE
mutations marginally affect iron absorption and rarely lead to
HH.
The molecular link between the HFE protein and the TfR1
raised the possibility that this regulatorymechanism of iron trans-
port may play a role in the pathogenesis of HH (Fleming et al.,
1999; Anderson et al., 2002). The answer to whether Hfe alters
cellular iron uptake by serving as a sensor mechanism in duo-
denal enterocytes was provided through the generation of mice
bearing a selective deﬁciency of Hfe in the duodenal entero-
cytes (Vujic Spasic et al., 2007). Surprisingly, mice lacking Hfe
in intestinal cells showed no iron accumulation in the liver nor
hepatic hepcidin deﬁciency overruling the traditional hypoth-
esis that duodenal Hfe played a gatekeeper role in controlling
systemic iron homeostasis (Vujic Spasic et al., 2007). The ques-
tion where Hfe acts to control iron homeostasis was revealed
through the generation of mice with selective deﬁciency of Hfe
in hepatocytes which recapitulated most of the anomalies within
iron metabolism observed in constitutive Hfe mutant mice and
HFE-HH patients (Adams, 2003; Wigg et al., 2003; Vujic Spa-
sic et al., 2008; Adams and Barton, 2010). Mice deﬁcient for
the hepatocytic-Hfe show decreased hepcidin expression which
led to uncontrolled iron uptake and iron accumulation in the
liver (Vujic Spasic et al., 2008). Vice versa, hepatocellular trans-
genic over-expression of Hfe in mice lacking endogenous Hfe
resulted in signiﬁcant upregulation of hepcidin and normaliza-
tion of transferrin saturation and liver iron levels (Schmidt et al.,
2008). Collectively, these data establish hepatocytic-Hfe as the reg-
ulator of hepatic hepcidin expression and imply that regulatory
cues involved in maintaining iron homeostasis are centered in the
liver.
HFE IS INVOLVED IN IRON-MEDIATED CONTROL OF HEPCIDIN
EXPRESSION VIA THE BMP/SMAD SIGNALING PATHWAY
The above investigations argue for the role of Hfe in hepatocytes
to regulate hepcidin expression and thus iron homeostasis. In the
last couple of years ﬁrst insights into to molecular mechanism
coupling Hfe to hepcidin expression have begun to emerge.
It is proposed that Hfe is sequestered by TfR1 protein in an
iron-sensing complex located in the hepatocyte cell membrane
(Figure 1) (Goswami and Andrews, 2006). The close interaction
between Hfe and TfR1 is disrupted upon binding of circulating
transferrin bound iron which binds with higher afﬁnity to TfR1
(Figure 1) (Goswami and Andrews, 2006). In vitro studies pro-
posed a model in which Hfe upon dissociation from Hfe/TfR1
complex, interacts with another HH protein, TfR2, and that this
partnership is enlarged by the contribution of amembrane-bound
bone morphogenetic protein (Bmp) co-receptor Hjv (Figure 1)
(Goswami and Andrews, 2006; D’Alessio et al., 2012). However a
direct interaction betweenHfe andTfR2 could not be conﬁrmed in
vivo suggesting that TfR2 may regulate hepcidin expression in an
Hfe-independent manner (Schmidt and Fleming, 2012). Impor-
tantly,Hfe-mediatedhepcidin expression is abolishedby the loss of
endogenous Hjv protein implicating for co-dependency between
Hfe and the Hjv (Schmidt et al., 2010). The Bmp co-receptor, Hjv,
is involved in transmitting the signals initiated upon binding of
Bmp ligands, the members of the multifunctional Tgf-β family
proteins, to two cognate serine/threonine kinase receptors, type I
and II located at the cell surface (Figure 1) (Miyazono et al., 2005;
Babitt et al., 2006; Babitt et al., 2007). This interaction induces
phosphorylation of the intracellular receptor-activated Smad pro-
teins 1/5/8 and subsequent binding of common Smad4 protein
to form an active transcriptional complex which directly regu-
lates the expression of numerous target genes including hepcidin
(Figure 1) (Miyazono et al., 2005; Babitt et al., 2006; Babitt et al.,
2007; Truksa et al., 2009). The lack of Hjv, Hfe, TfR2, or com-
bined Hfe and TfR2 deﬁciency signiﬁcantly impairs the activity
of the Bmp/Smad-signaling pathway resulting in a low hepcidin
expression and profound systemic iron overload (Babitt et al.,
2006; Corradini et al., 2009, 2011; Kautz et al., 2009; Ryan et al.,
2010; Vujic Spasic et al., 2013). Furthermore, mice deﬁcient for
hepatic Bmp type I receptors, Alk2 or Alk3 (Steinbicker et al.,
2011), or Smad4 expression (Wang et al., 2005), or for ubiqui-
tous Bmp6 expression (Andriopoulos et al., 2009; Meynard et al.,
2009) present with relatively low hepcidin levels in regard to
overall body iron overload. The Bmp/Smad signaling pathway
therefore emerges as the central signaling event for regulating
hepcidin transcription in hepatocytes. Recently, a contribution of
the Erk/Mapk signaling cascade to hepcidin regulation has been
proposed (Wallace et al., 2009) as its decreased signaling activity
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FIGURE 1 | Sensing of transferrin-bound iron and regulation of
hepcidin expression in hepatocytes. The iron-sensing process involves
binding of transferrin-bound iron to TfR1 causing a dissociation of Hfe from
the Hfe/TfR1 partnership, relocation of Hfe to TfR2 and presumably the
formation of a large membrane-bound complex composed of Hfe/TfR2/Hjv
and BMPRII and I. This hepatocyte-membrane complex activates
transduction cascade involving the phosphorylation of the Smad1/5/8 and
subsequent binding of common Smad4 protein to form a transcriptional
complex which directly activates hepcidin transcription. The Bmp/Smad
signaling is the central pathway for the regulation of hepcidin transcription.
Lack of Hfe and other components of the membrane-bound complex
severely impair the phosphorylation of Smad1/5/8 and consequently the
transcription of hepcidin. Combined deﬁciency of Hfe andTfR2 results in
decreased Erk/Mapk signaling activity in the liver, implicating that additional
or parallel signaling pathway to Bmp/Smad may be involved in the control of
hepatic hepcidin transcription.
in the liver was associated with the combined deﬁciency of Hfe
and TfR2 suggesting that additional, or parallel signaling path-
way to Bmp/Smad may control hepatic hepcidin transcription
(Figure 1).
THERAPEUTIC IMPLICATION OF ATTENUATED
BMP/SMAD-MEDIATED HEPCIDIN REGULATION IN HFE-HH
Given the fact that hepcidin levels are low in Hfe-HH and that Hfe
is involved in optimizing iron-response via Bmp/Smad signaling
activity in the liver, it would be expected that by modulating hep-
cidin levels and/or the activity of the Bmp/Smad pathway, the
iron homeostatic parameters in HFE-HH patients may be nor-
malized. In contrast to phlebotomy therapies that manipulate
the excess of iron, few pilot approaches were conducted with the
aim to target the defective molecular mechanisms underlying the
HFE-HH.
Short- and long-term hepcidin injections, or hepatic over-
expression of hepcidin transgene in Hfe-deﬁcient mice resulted
in successful reconstitution of hepcidin expression to the levels
present in wild type mice. Furthermore, high plasma iron levels
present in Hfe−/− mice were signiﬁcantly reduced by hepcidin
treatments, without affecting hepatic iron load which remained
inappropriately high in regard to hepcidin levels (Nicolas et al.,
2003; Laftah et al., 2004; Rivera et al., 2005; Viatte et al., 2006;
Moran-Jimenez et al., 2010). Neither has exogenous Bmp6 admin-
istration toHfe−/− mice succeeded to reduce hepatic iron burden,
although hepcidin expression was restored to the levels present
in wild type mice, followed by a signiﬁcant drop in serum iron
levels and redistribution of iron in the spleen and duodenum in
Hfe−/− mice (Corradini et al., 2010). Due to severe side-effect
(peritoneal calciﬁcation) that accompanied prolonged exogenous
Bmp6 treatment in mice (Corradini et al., 2010), the Bmp6 sub-
stitution cannot be currently considered as an optional therapy
for HH.
HFE-HEPCIDIN-DEPENDENT AND -INDEPENDENT CONTROL
OF IRON HOMEOSTASIS
The above data raise a critical question to whether Hfe-HH is an
exclusive consequence of defective Bmp/Smad signaling and low
hepcidin expression, or whether HH-associated pathologies may
be intensiﬁed or refractory to iron-depletion strategies or hep-
cidin substitution if Hfe exerts distinct, extra-hepatocytic functions
(Figure 2). Noteworthy, both Hfe and hepcidin are expressed in
several extra-hepatic tissues (e.g., heart, skeletal muscle, kidney,
lungs, thymus, duodenum) but so far, little is known whether
Hfe-hepcidin regulation is operating in these cells and how it may
impact on cellular and/or systemic iron homeostasis (Figure 2).
For example, general Hfe deﬁciency was associated with better
tolerance of Hfe−/− mice to severe blood loss in regard to wild
type mice or animals kept on an iron-rich diet (Ramos et al.,
2011). During erythropoietic stress conditions hepcidin expres-
sion is severely hampered which in turn signals for enhanced iron
absorption, iron mobilization from the stores and iron utiliza-
tion by the erythron. It was proposed that in addition to general
Hfe and hepcidin deﬁciency, selective Hfe actions in erythroid
cell may contribute to overall better tolerance of Hfe−/− mice to
severe blood loss by enhancing transferrin-bound iron uptake and
thus modulating erythroid iron homeostasis (Ramos et al., 2011)
(Figure 2). However a direct role of Hfe in erythroid cells and its
contribution to cellular and overall iron homeostasis remains still
to be conﬁrmed.
Furthermore, Hfe may be involved in controlling iron home-
ostasis in a non-hepcidin dependent manner. It was proposed that
Hfe may act to control iron release or iron uptake in cells since
expression of HFE protein in HT29 human colon carcinoma cells,
THP-1 cells, or in monocytes derived from HFE-HH patients
inhibited iron release from the cells and resulted in increased iron
accumulation without affecting iron uptake (Montosi et al., 2000;
Drakesmith et al., 2002; Davies and Enns, 2004). On the other
hand, over-expression of HFE in HeLa and hepatic HepG2 cells
decreased iron loading in these cells (Gao et al., 2008), suggesting
that HFE may exert distinct iron-regulatory functions depend-
ing on the site of its expression. In line with this, recent in vivo
studies demonstrated that Hfe actions in macrophages are not
required for the control of hepatic hepcidin expression (Makui
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FIGURE 2 | Beyond the hepatocytes. The regulatory cues controlling iron
metabolism are centered in the liver where hepatocytic-Hfe directs the
production of the liver iron hormone hepcidin. The lack of hepatocytic-Hfe
leads to inadequate production of hepcidin which results in increased iron
uptake by the duodenum, iron release from macrophages into the
circulation and deposition of the excess of iron in numerous tissues
causing systemic iron overload (indicated by black arrows). The actions of
the Hfe in extra-hepatocytic cells, such as erythroid and macrophages
(indicated by grey circle), have recently been proposed suggesting for
previously neglected functions of the Hfe in these cells. These selective
extra-hepatocytic functions of Hfe are involved in the control of local,
tissue-speciﬁc iron homeostasis however their impact on systemic iron
regulation and the relevance for the Hfe-HH associated pathologies
remains still to be discovered.
et al., 2005; Vujic Spasic et al., 2008) and that Hfe may display
hepcidin-independent iron-modifying effect in these cells (Garuti
et al., 2011) (Figure 2). Transplantation of Hfe+/+ donor liver
into Hfe−/− recipient mice improved hepatic hepcidin expression
and reduced the liver iron burden in Hfe−/− mice, being in line
with the initial clinical transplantation results (Garuti et al., 2011).
Surprisingly, liver macrophages (Kupffer cells) were not rescued
by the action of the donor, wild type hepatocytic-Hfe (Garuti et al.,
2011).
These observations bring up a tantalizing thought whether Hfe
is only required for the up regulation of hepcidin in response
to elevated iron levels and thus for the maintenance of cellular
and systemic iron pool, or the functions of this MHC-class I like
molecule may be uncoupled from the control of iron homeosta-
sis. Understanding distinct pathways that Hfe employs beyond
the hepatocytes and beyond hepcidin regulation may leap transla-
tional medicine research in that some symptoms assigned to HH
as a consequence of iron overload may be recognized appropri-
ately and may better be treated by organ-speciﬁc therapies rather
than systemic iron-depletion.
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